Thin IPO calendar hedge funds are zeroing in on biopharma
opalesque
4 months ago
63 views
With IPO activity muted, hedge funds are concentrating capital in biopharma companies with late-stage pipelines. Specialists see asymmetric upside in clinical catalysts despite sector volatility.... Article link
Continue Reading
Sign up for FREE to read the full article and access 129K+ alternative investment headlines.